LA JOLLA, Calif.–(BUSINESS WIRE)–Jan 28, 2021–
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its support and presentation in the Melanoma Research Foundation’s (“MRF”) “Ask the Expert” webinar series throughout the month of January.
The events featured leading dermatologists and industry experts to increase awareness and education on melanoma. A key focus of the series was the importance of early detection of skin cancer and the delays in skin cancer screenings and diagnosis resulting from the COVID-19 pandemic. The recorded webinars are accessible here.
The “Ask the Expert” webinars took place on the MRF Facebook page with the following speakers:
- Jan. 7, 2021: Dr. Neal Bhatia, Therapeutics Clinical Research.
- Jan. 14, 2021: Dr. Ann Mazor Reed, Rendon Center Dermatology & Aesthetic Medicine and Skin Care Research.
- Jan. 21, 2021: Dr. Stephanie Diamond, Advanced Dermatology and Dr. Chris Adigun, Dermatology & Laser Center of Chapel Hill.
- Jan. 28, 2021: Dr. Julie Karen, Complete Skin MD and New York University Langone Medical Center.
“Education, early detection and prevention are some of the most powerful tools to fight melanoma,” said Burkhard Jansen, M.D., chief medical officer of DermTech. “We are proud to support the MRF and its ‘Ask the Expert’ sessions in raising awareness of this aggressive form of skin cancer.”
“This informative series is a vital element to preventing melanoma in as many people as possible,” said Kyleigh LiPira, MBA, chief executive officer of the MRF. “Our work with DermTech complements our mission of providing the necessary insight and resources to vigilantly prevent and detect melanoma. We are excited to kick off 2021 with new sessions and conversations.”
For more information on the “Ask the Expert” Facebook Live webinars, including additional upcoming topics for discussion, please visit the MRF Facebook page here.
About DermTech
DermTech is the leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by our non-invasive skin genomics platform. DermTech’s mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology care, and to improve the lives of millions. DermTech provides genomic analysis of skin samples collected non-invasively using an adhesive patch rather than a scalpel. DermTech markets and develops products that facilitate the early detection of skin cancers, and is developing products that assess inflammatory diseases and customize drug treatments. For additional information on DermTech, please visit DermTech’s investor relations site at: www.DermTech.com.
Forward-looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the performance, patient benefits, cost-effectiveness, commercialization and adoption of DermTech’s products, including the Smart Sticker platform, and the market opportunity therefor. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Quarterly Report on Form 10-Q filed by DermTech with the Securities and Exchange Commission (the “SEC”), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com:https://www.businesswire.com/news/home/20210128005964/en/
CONTACT: DermTech
Sarah Dion
[email protected]
858.450.4222
Crowe PR
Sarah Gallagher
[email protected]
224.406.4709
Melanoma Research Foundation
Lorrie Beth Miley
[email protected]
202.742.5913
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH MEDICAL DEVICES HEALTH ONCOLOGY
SOURCE: DermTech, Inc.
Copyright Business Wire 2021.
PUB: 01/28/2021 04:30 PM/DISC: 01/28/2021 04:30 PM
http://www.businesswire.com/news/home/20210128005964/en
